Biogen Ma Inc.

Biogen Idec Ma Inc.

Genetics Institute, Inc.

Centre National De La Recherche Scientifique

Cnrs

University Pierre and Marie Curie

Sha Mi

R Blake Pepinsky

Gnanasambandam Kumaravel

John M McCoy

Arthur G Taveras

Alexey Alexandrovich Lugovskoy

Kevin Guckian

Bin Ma

Zhaohui Shao

Christilyn Graff

Zhili Xin

Guo Zhu Zheng

Richard Dana Caldwell

Edward Yin-Shiang Lin

Jermaine Thomas

Lei Zhang

Lihong Sun

Kenneth A Jacobs

Hairuo Peng

Daniel H S Lee

Deping Wang

Samuel Goldman

Debra D Pittman

McKeough Carlin

Kerry Kelleher

Steven Neben

Joanne Giannotti

Margaret M Golden-Fleet

Ellen A Garber

Kenneth Rhodes

Steven Donald Miklasz

Jeffrey L Browning

Edward R LaVallie

Lisa A Racie

David Merberg

Maurice Treacy

Cheryl Evans

Ellen A Garber Stark

Diego Cadavid

Alain Chedotal

Frederic Bernard

Vincent Jung

John Mccoy

Steven D Miklasz

H S Lee Daniel

Christilyn P Graff

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

S1P modulating agents

Methods, compositions and kits comprising an anti-LINGO antibody molecule are described herein useful for detecting and/or treating a CNS demyelinating disease.

LINGO-1 antagonists and uses for treatment of demyelinating disorders

Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

SIP modulating agents

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

ATX modulating agents

Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). 

Compounds that are S1P modulating agents and/or ATX modulating agents

The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.

LINGO-2 antagonists for treatment of conditions involving motor neurons

Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.

Compositions comprising antibodies to LINGO or fragments thereof

Compounds of formula (I) can modulate the activity of autotaxin (ATX).

Compounds of formula (I) or (II) can modulate the activity of SIP receptors.

The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a Sema6A polypeptide.

Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation

The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist.

Screening methods for identifying Sp35 antagonists

Growing community of inventors

Belmont, MA, United States of America

Sha Mi